Investor Relations

Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

Read Press Release

Annual Meeting of Shareholders

View All Events

Latest Financial Results

Q2 2021

Quarterly Results

Ended Jun 30, 2021

Stock Information

Symbol NYSE American: OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Company Overview

Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.

Contact Information

Investor Relations
LHA Investor Relations
Kim Golodetz
Senior Vice President, Principal
T: 212-838-3777
kgolodetz@lhai.com

Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000